statut,NCTId,eudraCT,completion_year,clinical_trial_title,acronym,results_1y,results_3y
ðŸŸ¥,NCT00121121,,2005,A Phase Ib Vaccine Trial Evaluating the Safety and Immunogenicity of HIV Lipopeptides by Two Administration Routes (Intramuscular And Intradermal) in Healthy Adult Volunteers. ANRS VAC16 Trial,,False,False
ðŸŸ¥,NCT00196586,,2006,Pilot Study of Addition of IL-2 to Pegylated Interferon Alpha 2a and Ribavirin for the Treatment of Chronic Hepatitis C in HIV-HCV Coinfected Patients Non Responders to Three Months of Therapy With Pegylated Interferon Alpha 2a and Ribavirin. ANRS HC09 SECOIIA,,False,False
ðŸŸ¥,NCT00120185,,2006,Study of the Immunological Efficacy of Using Subcutaneous Interleukin-2 (IL-2) in Antiretroviral NaÃ¯ve HIV-1-Infected Subjects With a CD4 Cell Count Above 300/mm3. ANRS 119 Trial INTERSTART,,False,False
ðŸŸ¥,NCT00148863,,2007,Pilot Study on Interferon Gamma in Association With Peg-Interferon Alpha 2a and Ribavirin Among Patients With a Chronic Hepatitis C and Non Responders to the Association of Peg-Interferon Alpha 2b or 2a and Ribavirin ANRS HC16 Gammatri,,False,False
ðŸŸ¥,NCT00117494,,2007,Randomised Comparative Study of the Efficacy and Safety of Rosuvastatin and Pravastatin in Dyslipidemic Patients Treated With Antiretroviral Agents. Anrs 126,,False,False
ðŸŸ¥,NCT00120367,,2007,Early Intensification of Combination Antiretroviral Therapy Including FUZEONÂ® in the Treatment of Progressive Multifocal Leucoencephalopathy During HIV-1 Infection ANRS 125 Trial,,False,False
ðŸŸ¥,NCT00121758,,2007,Randomised Double Blinded Phase II AIDS Vaccine Study Comparing Immunogenicity and Safety of 3 Doses of Lipopeptide (LIPO-5) Versus Placebo in Non Infected HIV Volunteers (ANRS VAC 18),,False,False
ðŸŸ¥,NCT00122603,,2007,Efficacy and Safety of Regimens Restricted to a Combination of Two Boosted Protease Inhibitors as Potent Antiretroviral Therapy in HIV-1 Infected Patients. ANRS 127 2IP,,False,False
ðŸŸ¥,NCT00118677,,2007,Long-Term Supervised Treatment Interruption in HIV-Infected Patients Who Started Antiretroviral Treatment With CD4 Over 350/mm3 and Plasma HIV RNA Below 50 000/mL ANRS 116 Trial SALTO,,False,False
ðŸŸ¥,NCT00454337,,2008,Randomized Non-inferiority Study Comparing a Strategy Maintaining Current Enfuvirtide-based Antiretroviral Therapy to a Strategy Replacing Enfuvirtide by an Integrase Inhibitor (Raltegravir) in HIV-1 Infected Subjects With Plasma Hiv-1 RNA Levels Below 400 Copies Per ml.ANRS 138 EASIER,EASIER,False,False
ðŸŸ¥,NCT00528060,,2008,"Pilot Study to Measure Exposure to Atazanavir, as a Component of Pharmacokinetic Parameters and Adherence Measured With MEMS in Naive HIV-infected Patients Treated Once Daily With Atazanavir Combined to Ritonavir and to Tenofovir/Emtricitabine. ANRS 134 Cophar 3",ANRS134COPHAR3,False,False
ðŸŸ¥,NCT00120757,,2008,"Efficacy of Alendronate Versus Placebo in the Treatment of HIV-1 Associated Osteoporosis, a Multicenter, Randomized, Controlled Trial. ANRS 120 Fosivir",,False,False
ðŸŸ¥,,2007-003203-12,2008,"PharmacocinÃ©tique de lâ€™atazanavir chez des patients infectÃ©s par le VIH, traitÃ©s en premiÃ¨re ligne par lâ€™association atazanavir+ritonavir et emtricitabine+tÃ©nofovir en prise unique.",COPHAR-3,False,False
ðŸŸ¥,NCT00113282,,2008,Study of the Immunological Efficacy of Adding Subcutaneous Interleukin-2 (IL-2) to an Optimized Antiretroviral Regimen in HIV-1-infected Subjects Experiencing Therapeutic Failure on an Ongoing Antiretroviral Combination With a CD4 Cell Count â‰¤ 200/mm3 ANRS 123 Trial,,False,False
ðŸŸ¥,,2007-000162-20,2008,"Essai randomisÃ© de non-infÃ©rioritÃ© comparant une stratÃ©gie de maintien du traitement antirÃ©troviral en cours Ã  une stratÃ©gie de substitution de lâ€™enfuvirtide par un inhibiteur de lâ€™intÃ©grase (MK 0518) chez des sujets infectÃ©s par le VIH-1, ayant un ARN VIH-1 plasmatique infÃ©rieur Ã  400 copies/ml.",EASIER,False,False
ðŸŸ¥,,2007-000670-23,2009,"Essai pilote Ã©valuant un traitement antirÃ©troviral associant le MK-0518, le darunavir/ritonavir (TMC114/r) et lâ€™etravirine (TMC125) chez les patients infectÃ©s par le VIH-1, en Ã©chec virologique et porteurs de virus multi-rÃ©sistants.",TRIO,False,False
ðŸŸ¥,NCT00196664,,2009,"Assessment of the Efficacy of Paroxetine in the Prevention of Depressive Syndrome in Patients With Chronic Hepatitis C Treated by PEG-Interferon Alfa Plus Ribavirin. Multicentric, Double-Blinded, Randomized Study. ANRS HC18 Paropeg",,False,False
ðŸŸ¥,NCT00122616,,2009,Efficacy of Pegylated Interferon on Liver Fibrosis in Co-infected Patient With HIV and C Hepatitis Who Failed to Active Treatment for HCV. ANRSHC12 Fibrostop,,False,False
ðŸŸ¥,NCT00302822,,2009,Enfuvirtide for the Initial Phase of Antiretroviral Therapy in HIV-infected Patients With High Risk of Clinical Progression : ANRS 130 APOLLO,,False,False
ðŸŸ¥,NCT00115609,,2009,Pilot Trial Evaluating Once Daily Triple Combination Antiretroviral Therapy With Tenofovir-Emtricitabine and Efavirenz in HIV-1 Infected Patients With Mycobacterium Tuberculosis Infection ANRS129 BKVIR,,False,False
ðŸŸ¥,NCT00460382,,2009,"Prospective Clinical Trial to Assess Safety and Efficacy of DRV/r(TMC 114/r), ETV(TMC 125) and MK-0518 in Addition to OBT in HIV-1 Infected Patients With Limited to No Treatment Options ANRS 139 TRIO",ANRS139 TRIO,False,False
ðŸŸ¥,NCT00490074,,2009,A Phase I/II Trial to Compare the Immunogenicity and Safety of 3 DNA C Prime Followed by 1 NYVAC C Boost to 2 DNA C Prime Followed by 2 NYVAC C Boost,EV03/ANRSVAC20,False,False
ðŸŸ¥,NCT00647205,,2010,Evaluation of 2 Interferon Î³ Assays (QuantiFERON TB Gold In-TubeÂ® and T-SPOT.TBÂ®) in the Diagnosis of Latent Tuberculosis in HIV-infected Patients.ANRS EP 40 QUANTI SPOT,,False,False
ðŸŸ¥,NCT01039220,,2010,Incidence of H1N1v Influenza-like Illness and Risk Factors for Serious Influenza Forms in HIV Infected Patients,ANRS 2H,False,False
ðŸŸ¥,NCT00536627,,2010,"Randomised, Opened, Multicentre Phase I/II Trial in Patients With Chronic Hepatitis B With HBV VL < 12 IU/ml and Under Treatment With NRTI, Which Evaluated Efficacy and Tolerance of Vaccination With Naked DNA on Viral Replication After Analogs' Treatment Interruption. ANRS HB02 VAC-ADN",VAC-ADN,False,False
ðŸŸ¥,NCT01038401,,2010,Characterization of the Residual Replication of HIV-1 in the Gut-associated Lymphoid Tissue in Patients Receiving Effective Highly Active Antiretroviral Therapy: the ANRS EP 44 Study,EP 44,False,False
ðŸŸ¥,NCT01008813,,2010,A Randomized Phase II Trial to Evaluate the Immunogenicity and Safety of an Adjuvanted A(H1N1)v Influenza Vaccine and a Non-adjuvanted A(H1N1)v Influenza Vaccine in HIV-infected Patients (ANRS 151 Hifluvac),,False,False
ðŸŸ§,NCT00383734,,2010,"Randomized, Comparative, Multicenter, Patient-blinded Trial of the Safety and Efficacy of Intradermal Injections of Polylactic Acid (Newfill TM) Versus Polyacrylamid Gel (Eutrophill) in the Treatment of Facial Lipoatrophy in HIV-infected Patients ANRS 132 SMILE",,False,True
ðŸŸ¥,,2009-016226-13,2010,Etude de phase II randomisÃ©e Ã©valuant l'immunogÃ©nicitÃ© et la tolÃ©rance du vaccin antigrippal A(H1N1)v adjuvantÃ© comparativement au vaccin antigrippal A(H1N1)v non adjuvantÃ© chez des patients infectÃ©s par le VIH (ANRS 151 HIFLUVAC),HIFLUVAC,False,False
ðŸŸ¥,NCT00574652,2006-004039-31,2010,"ANRS HC 21 VASCU IL-2, Evaluation of the Cellular Immune Response, Clinical Efficacy and Tolerance After IL-2 Therapy in HCV-related Vasculitis Patients, Resistant to Conventional Therapy.",VASCU-IL2,False,False
ðŸŸ§,NCT00657397,,2011,Initialization of Methadone in Primary Care; a Randomized Intervention Research for Preventing HCV Transmission Practices. ANRS Methaville,Methaville,False,True
ðŸŸ¥,NCT01164462,,2011,,DRAG,False,False
ðŸŸ¥,NCT00944541,,2011,Pilot Study Evaluating Maraviroc (CelsentriÂ®)Intensification Benefit in HIV Infected Patients Presenting Insufficient Immune Restoration Despite Controlled Viral Load With Antiretroviral Treatment. ANRS 145 MARIMUNO,145 MARIMUNO,False,False
ðŸŸ¥,NCT00421551,,2011,"A Randomized Multicenter Study With Non-inferiority Hypothesis, Comparing the Availability to Maintain a Complete Viral Suppression by a Monotherapy of Darunavir/r to a NRTI Containing Regimen Including Darunavir/r, in HIV-1 Infected Patients With Previous Prolonged Complete Viral Suppression. ANRS 136 MONOI",,False,False
ðŸŸ¥,,2009-011171-76,2011,Etude pilote Ã©valuant lâ€™intÃ©rÃªt dâ€™une intensification par maraviroc (CelsentriÂ®) chez des patients infectÃ©s par le VIH-1 prÃ©sentant une restauration immunitaire insuffisante malgrÃ© une charge virale contrÃ´lÃ©e par un traitement anti-rÃ©troviral.,MARIMUNO,False,False
ðŸŸ¥,,2006-005962-38,2011,"Essai randomisÃ© de non-infÃ©rioritÃ© comparant la capacitÃ© Ã  maintenir le succÃ¨s virologique dâ€™une stratÃ©gie de traitement simplifiÃ© par une monothÃ©rapie dâ€™inhibiteur de protÃ©ase boostÃ©, le darunavir/r (TMC114/r), par rapport au maintien dâ€™une trithÃ©rapie comportant 2 inhibiteurs nuclÃ©osidiques de la transcriptase inverse (INTI) associÃ©s au darunavir/r (TMC114/r) chez des patients infectÃ©s par le VIH-1 en succÃ¨s immunovirologique.",MONOI,False,False
ðŸŸ¥,NCT00391638,,2012,Pilot Study on Efficacy and Tolerance of Peg-interferon Alpha-2a (Pegasys) Added to Tenofovir DF and Emtricitabine (Truvada) in AGHBe Positive HBV-HIV Co-infected Patients. ANRS HB 01 EMVIPEG.,HB01EMVIPEG,False,False
ðŸŸ¥,NCT01413152,,2012,EVALUATION DU RISQUE RESIDUEL DE TRANSMISSION DU VIH CHEZ DES HSH TRAITES AYANT UNE CHARGE VIRALE PLASMATIQUE INDETECTABLE,EP 49 EVARIST,False,False
ðŸŸ¥,NCT01065207,,2012,ANRS HIV CONTROLLERS NATIONAL OBSERVATORY,ANRS CO18,False,False
ðŸŸ¥,,2008-000859-10,2012,"Etude pilote, multicentrique, Ã©valuant lâ€™efficacitÃ© dâ€™un traitement anti VHC optimisÃ© (induction par 360Âµg/S de PegIFN-alpha 2a + 18mg/kg/j de RBV pendant 6 mois puis en fonction de la rÃ©ponse virologique Ã  S12, allongement jusqu'Ã  S72 de la bithÃ©rapie anti VHC, avec mesures d'accompagnement) sur la rÃ©ponse virologique soutenue chez des patients VHC de gÃ©notype 1 et 4, non rÃ©pondeurs et co-infectÃ©s par le VIH.",ETOC,False,False
ðŸŸ¥,NCT00820118,,2012,"ARNS 141 TIPI : A Pilot Trial to Assess the Ability of an Intermittent Antiretroviral Therapy in Maintaining an Immunological Stability in Antiretroviral naÃ¯ve HIV Infected Adults, With CD4 Count Above 500/mm3",TIPI,False,False
ðŸŸ¥,NCT00480792,,2012,"Open-label, Randomized, and Multicentric Phase III Clinical Trial Comparing Three Strategies of Vaccination Against the Virus of Hepatitis B in HIV-1-infected Patients With CD4-positive T-lymphocytes Counts Above 200 permm3 ANRS HB 03 VIHVAC-B",VIHVAC-B,False,False
ðŸŸ©,NCT00424814,,2012,Prevention of HIV1 Mother to Child Transmission Without Nucleoside Analogue Reverse Transcriptase Inhibitors in the Pre-partum Phase. A Multicenter Randomised Phase II/III Open Label Study With a Group of 100 Pregnant Women Receiving Lopinavir/Ritonavir and a Group of 50 Receiving Lopinavir/Ritonavir Plus Zidovudine and Lamivudine. ANRS 135 Primeva,,True,True
ðŸŸ§,NCT00901524,,2012,"ANRS HC20 Pilot Study, Multicenter, Assessing the Effectiveness of an Optimized Anti HCV (360Î¼g/Week Induction of PegIFN-alpha2a + 18mg/kg/j of RBV for 6 Months and Then Depending on the Virological Response to S12, Elongation up S72 to the Dual Anti HCV, With Accompanying Measures) on Sustained Virological Response in Patients With HCV Genotype 1 and 4 Non Responders and Co-infected With HIV.",ETOC,False,True
ðŸŸ§,NCT00822315,,2012,"Phase II Open-label Randomized Multicenter Trial to Compare the Efficacy and Safety of Two Different Doses of Raltegravir and Efavirenz, All in Combination With Tenofovir and Lamivudine, in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis",,False,True
ðŸŸ§,NCT01033760,,2013,Optimisation of Primary HIV1 Infection Treatment (ANRS 147 OPTIPRIM),,False,True
ðŸŸ¥,NCT00323804,,2013,"Randomized, Double-blind, Placebo-controlled Multicenter Study Evaluating the Interest of a Long-term (3 Years) Treatment With Peginterferon Alfa-2b and Ribavirin on Liver Fibrosis in Non-responder Chronic Hepatitis C Patients.",,False,False
ðŸŸ§,NCT01226446,,2013,Multicenter Open and Prospective Trial Assessing the Efficacy of Vitamin D Supplementation in Addition to Pegylated Interferon Plus Ribavirin in Null-Responders Patients With Chronic Viral Hepatitis C Genotype 1 or 4,ANRS VITAVIC,False,True
ðŸŸ§,NCT00670839,,2013,"Open-label, Randomized, and Multicenter Phase III Clinical Trial Comparing Immunogenicity of Double-dose (40 Âµg at S0, S4 and S24), Versus Standard Dose Vaccination (20 Âµg at S0, S4 and S24), Against Hepatitis B Virus in HIV-1-infected Patients Without Any Previous Immune Response After Primary Immunization Plus One Single Boost",B-BOOST,False,True
ðŸŸ§,NCT01066962,,2013,An Open-label Randomised Two-year Trial Comparing Two First-line Regimens in HIV-infected Antiretroviral naÃ¯ve Subjects: Darunavir/r + Tenofovir/Emtricitabine vs. Darunavir/r + Raltegravir (ANRS 143/NEAT 001),ANRS 143,False,True
ðŸŸ¥,,2009-015113-44,2013,An open-label randomised two-year trial comparing two first-line regimens in HIV-infected antiretroviral naÃ¯ve subjects:  darunavir/r + tenofovir/emtricitabine vs. darunavir/r + raltegravir,,False,False
ðŸŸ¥,,2009-014616-36,2013,"Etude pilote de la pharmacocinÃ©tique, de la tolÃ©rance et de lâ€™efficacitÃ© du raltÃ©gravir associÃ© Ã  deux molÃ©cules actives parmi les analogues nuclÃ©osi(ti)diques et lâ€™enfuvirtide, avant et aprÃ¨s transplantation hÃ©patique chez des patients VIH+ en insuffisance hÃ©patique sÃ©vÃ¨re.",LIVERAL,False,False
ðŸŸ©,NCT01332955,,2013,Pilot Study of PegInterferon-Ribavirin-Telaprevir Efficacy and Tolerability in HIV-HCV Coinfected Patients Who Had Previously Failed a PegInterferon-Ribavirin Regimen. (ANRS HC26 TelapreVIH),TelapreVIH,True,True
ðŸŸ¥,NCT00116454,,2013,A Randomized and Multicenter Trial for Hepatocellular Carcinoma Adjuvant Treatment by Lipiocis,Lipiocis,False,False
ðŸŸ¥,,2009-015121-37,2013,Etude multicentrique randomisÃ©e ouverte comparant la rÃ©duction virale et la tolÃ©rance de lâ€™association IFN alpha-2b XL + ribavirine versus IFN peg alpha-2b + ribavirine chez des patients atteints dâ€™hÃ©patite chronique C de gÃ©notype 1,COAT-IFN,False,False
ðŸŸ¥,NCT01022476,,2013,"A Pilot Study of Pharmacokinetics, Tolerance and Efficacy of Raltegravir Combined to Two Fully Active Molecules Among Nucleosi(ti)de Analogs and Enfuvirtide Before and After Liver Transplant in HIV Infected Patients With End Stage Liver Disease (ANRS 148 LIVERAL)",LIVERAL,False,False
ðŸŸ¥,NCT00265642,,2013,Study of the Effects of a Sartan on Hepatic Fibrosis Progression in Chronic Viral Hepatitis C,Fibrosar,False,False
ðŸŸ¥,NCT00946595,,2014,A Study Comparing Efficacy and Tolerance of Two Maintenance Strategies : a Monotherapy With Lopinavir/Ritonavir or a Single-tablet Triple Therapy by Efavirenz/Emtricitabin/Tenofovir in HIV-1 Infected Patients With HIV RNA Below 50 cp/mL,ANRS 140 DREAM,False,False
ðŸŸ©,NCT01725542,,2014,"Pilot Study to Assess the Efficacy and Tolerance to a QUadruple Therapy With Asunaprevir , Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a, in HIV-HCV Genotype 1 or 4 Coinfected Patients Previously Null Responders to a Standard Pegylated Interferon -Ribavirin Regimen",QUADRIH,True,True
ðŸŸ¥,NCT01207986,,2014,Early Lung Cancer Diagnosis in HIV Infected Population With an Important Smoking History With Low Dose CT: a Pilot Study,EP48 HIV CHEST,False,False
ðŸŸ¥,NCT00918307,,2014,Comparison of the Efficacy and Safety of Varenicline Versus Placebo for Smoking Cessation Among HIV-infected Patients. A Randomized Double Blind Controlled Trial,Inter-ACTIV,False,False
ðŸŸ§,NCT01335529,,2014,"Pilot Study to Assess the Efficacy and Safety of Boceprevir, in Combination With Peg-Interferon Alfa and Ribavirin, in Patients With HCV/HIV Co-infection Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin",BocepreVIH,False,True
ðŸŸ¥,NCT02125500,2013-002607-33,2015,Pilot Study to Assess Efficacy and Safety of Sofosbuvir/Ledipasvir (GS-5885) Fixed-dose Combination in NS3/4A Protease Inhibitor-experienced Subjects With HCV Genotype 1 Infection and HIV Co-infection,,False,False
ðŸŸ¥,NCT01453192,,2015,"National, Multicenter, Phase III Prospective Trial About Clinical and Immunological Follow-up After Renal Transplantation in HIV-1 Infected Patients With End Stage Chronic Renal Insufficiency",ANRS153TREVE,False,False
ðŸŸ§,NCT01605890,,2015,"ANRS 159 VIH-2 : Trial Evaluating a First Line Combination Therapy With Raltegravir, Emtricitabine and Tenofovir in HIV-2 Infected Patients",VIH-2,False,True
ðŸŸ¥,NCT01463956,,2015,Pilot Study on the Efficacy of Pegylated Interferon-Ribavirin-Boceprevir Triple Therapy in Patients Infected With Genotype 1 HCV With Cirrhosis and Awaiting Liver Transplantation (ANRS HC 29 BOCEPRETRANSPLANT),,False,False
ðŸŸ¥,NCT01952587,,2015,Frequency and Functional Impact of the c.32A>T Genetic Polymorphism of TLR7 in Women Infected With HIV-1 : the ANRS EP53 Study,X LIBRIS,False,False
ðŸŸ¥,NCT02107365,,2015,"Pilot Study to Assess Efficacy and Safety of a Quadruple Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Non-responders to Pegylated Interferon-Ribavirin Regimen",,False,False
ðŸŸ¥,NCT02038842,,2016,Phase I/II Open-label Randomized Multicenter Trial to Assess Immunogenicity and Safety of 4 Prime-boost Combinations of HIV Vaccine Candidates (MVA HIV-B/ LIPO-5; LIPO-5/MVA HIV-B; GTUÂ®-MultiHIV B / LIPO-5; GTUÂ®-MultiHIV B/MVA HIV-B) in Healthy Volunteers at Low Risk of HIV Infection,VRI01,False,False
ðŸŸ©,NCT01473472,,2016,On Demand Antiretroviral Pre-exposure Prophylaxis for HIV Infection in Men Who Have Sex With Men,IPERGAY,True,True
ðŸŸ¥,NCT01899196,,2016,EPICARDIAL ADIPOSE TISSUE AND CORONARY RISK IN HIV-INFECTED PATIENTS,ANRS EP 52,False,False
ðŸŸ¥,NCT02093754,,2016,Assessing the Severity of Metabolic-related Liver Injuries in Aging HIV-monoinfected Patients: a European Multicentre Study,ANRS ECHAM,False,False
ðŸŸ§,NCT02157311,,2016,"Evaluation of the Capacity of a Weekly Strategy of 4 Consecutive Days on Treatment Followed by 3 Days Off Treatment, in HIV-1 Infected Patients With Undetectable Viral Load for at Least 12 Months, to Maintain a Virological Success With This Intermittent Maintenance Therapy After a Successful Continuous Induction Therapy.",ANRS162-4D,False,True
ðŸŸ§,NCT02384967,,2016,"Phase II Trial Assessing the Efficacy of a Reduced Dose Strategy of Darunavir to 400 mg/d in HIV-1 Infected Patients Virologically Suppressed Under a Once Daily Regimen Including Darunavir 800 mg/d and Two Nucleoside Reverse Transcriptase Inhibitors (NRTI), to Maintain the Viral Load Lower Than 50 Copies / mL at 48 Weeks of Treatment",DARULIGHT,False,True
ðŸŸ¥,NCT01348308,,2016,"Optimized Phase III Trial of Immuno-stimulation With Maraviroc, a CCR5 (Chemokine Receptor 5) Antagonist, Combined With Anti Retroviral Therapy in Advanced, Late Diagnosed HIV-1 Infected Patients With an AIDS-defining Event and/or CD4 (Cluster of Differentiation 4) Counts Below 200 Cells/mmÂ³. ANRS 146 OPTIMAL",OPTIMAL,False,False
ðŸŸ§,NCT02592174,,2017,"Prevalence, Characteristics and Risk Factors of HIV-Associated Neurocognitive Disorders in Subjects Between the Ages of 55 and 70 Years: An Exposed/Unexposed Cross Sectional Study",HAND55-70,False,True
ðŸŸ¥,NCT02527096,,2017,A Pilot Trial Evaluating Maintenance Therapy With Lamivudine(EpivirÂ®) and Dolutegravir(TivicayÂ®) in Human Immunodeficiency Virus 1 (HIV-1) Infected Patients Virologically Suppressed With Triple HAART - ANRS 167 Lamidol,,False,False
ðŸŸ¥,NCT01492985,,2017,Evaluation of a Therapeutic Immunization Strategy Associating a DNA Vaccine (GTU-MultiHIV B) Followed by a Lipopeptide Vaccine (LIPO-5) in the Control of Viral Replication Following Antiretroviral Treatment Interruption in HIV-1 Infected Patients With a CD4 Cell Count â‰¥ 600/mm3,,False,False
ðŸŸ©,NCT01426243,,2017,The Yellow Fever Vaccine Immunity in HIV Infected Patients : Development of New Assays for Virological and Immunological Monitoring in HIV Infected Patient,EP46 NOVAA,True,True
ðŸŸ¥,NCT02099474,2013-004571-12,2017,Evaluation of the Pharmacokinetic Properties and the Tolerance of Raltegravir During the Third Trimester of Pregnancy,ANRS 160 RalFE,False,False
ðŸŸ§,NCT02273765,,2018,"Phase III Open-label Randomized Multicenter Trial to Assess the Non-inferiority of Raltegravir Compared With EFavirenz, Both in Combination With LAmivudine and TEnofovir, in ART-naÃ¯ve HIV-1-infected Patients Receiving Rifampin for Active TuBerculosis",REFLATE TB2,False,True
ðŸŸ¥,NCT01269632,,2018,Long Term Evaluation of Young Adults Born to HIV-infected Mothers. A Cohort of Young Adults Infected With HIV Since Birth or During Childhood,CO19 COVERTE,False,False
ðŸŸ¥,NCT01942655,,2018,ANRS RF002 Intestipax : Interleukin-23 (IL-23)/Interleukin-12 (IL-12) Imbalance and T Lymphocyte Polarization in HIV Infection,INTESTIPAX,False,False
ðŸŸ¥,NCT01895920,,2018,,TRANSBioHIV,False,False
ðŸŸ¥,,2013-002996-16,2018,"ANRS SHS155 STIMAGO: Pilote study to evaluate the benefits and the risks of methylphenidate for the treatment of cocain dependence. 
 
 
 
 ANRS SHS155 STIMAGO : Etude pilote pour lâ€™Ã©valuation des bÃ©nÃ©fices et des risques du mÃ©thylphÃ©nidate pour la prise en charge de la dÃ©pendance Ã  la cocaÃ¯ne.","ANRS SHS155 STIMAGO 
 
 
 ANRS SHS155 STIMAGO",False,False
ðŸŸ§,NCT02212379,,2018,Dual Therapy Combining Raltegravir With Etravirine Maintains a High Level of Viral Suppression Over 96 Weeks in Long-term Experienced HIV-infected Individuals Over 45 Years on a PI-based Regimen: Results From the Phase II ANRS 163 ETRAL Study,,False,True
ðŸŸ¥,NCT02906137,,2020,Altered Homing of T Lymphocytes to the Gut and Poor Immune Reconstitution of the Intestinal Mucosa in Treated HIV-infected Individuals,GALT,False,False
ðŸŸ¥,NCT02738502,,2020,An Open-label Phase II Pilot Study of Prevention of Perinatal Transmission of HIV-1 Without Nucleoside Reverse Transcriptase Inhibitors,MONOGEST,False,False
ðŸŸ¥,NCT02987530,,2020,"Phase III Multicenter Randomized Trial Evaluating in Patients at the Time of the Primary HIV-1 Infection, the Impact on the Viral Reservoir of a Combination Including Tenofovir/Emtricitabine and Dolutegravir or Tenofovir/Emtricitabine and Darunavir/Cobicistat",OPTIPRIM-2,False,False
ðŸŸ¥,NCT03671291,,2021,National Survey on Missed Opportunities to Pre-exposure Prophylaxis for Prevention of Human Immunodeficiency Virus-infection.,,False,False
ðŸŸ©,NCT04008927,,2021,Towards Ending HCV Infection Among Active Drug Users: a Community-based Intervention in Montpellier.,ICONE,True,True
ðŸŸ¥,NCT05311865,,2022,Transmission of Covid-19 During Clubbing Events in Closed Places,ITOC,False,False
ðŸŸ¥,NCT04133012,,2023,A Prospective Study Aiming to Determine the Cartography of Virological Reservoir Related to Antiretroviral Concentrations in Chronic HIV-1 Patients Treated With a First Line of Dolutegravir and Associated Nucleoside / Nucleotide Reverse Transcriptase Inhibitors (NRTIs).,DOLUVOIR,False,False
ðŸŸ¥,NCT04824638,,2023,A Phase II Trial Assessing Immunogenicity and Safety of COVID-19 mRNA Vaccine BNT162b2 in Adult Volunteers With no History of SARS-CoV-2 Infection Administered With Two Doses of Vaccine (D1-D29) and in Adult Volunteers With Documented History of SARS-CoV-2 Infection (of More Than 5 Months) Administered With Only One Dose of Vaccine,CoviCompareP,False,False
ðŸŸ¥,NCT04120415,,2023,"EHVA T02 (European HIV Vaccine Alliance Therapeutic Trial 02)/ANRS VRI07: A Phase II Randomised, Placebo-controlled Trial of Vedolizumab With or Without Therapeutic HIV MVA Vaccine in Individuals Who Started Antiretrovirals During Primary or Chronic Infection",,False,False
ðŸŸ¥,,2017-000040-17,,"Randomized, open-label and multicentric trial evaluating the non-inferiority of antiretroviral treatment taken 4 consecutive days per week versus continuous therapy 7/7 days per week in HIV-1 infected patients with controlled viral load under antiretroviral therapy 
 
 
 Essai multicentrique, en ouvert, randomisÃ© en 2 groupes parallÃ¨les, Ã©valuant la non-infÃ©rioritÃ© dâ€™un traitement de maintenance Ã  4 jours consÃ©cutifs sur 7 versus la poursuite du traitement antirÃ©troviral en continu, chez des patients en succÃ¨s thÃ©rapeutique sous ARV.","QUATUOR 
 
 
 QUATUOR",False,False
ðŸŸ¥,,2021-000509-26,,"A phase II trial assessing immunogenicity and safety of COVID-19 mRNA Vaccine BNT162b2 in adult volunteers with no history of SARS CoV-2 infection administered with two doses of vaccine (D1-D29) and in adult volunteers with documented history of SARS CoV-2 infection (of more than 6 months) administered with only one dose of vaccine 
 
 
 Essai de phase II Ã©valuant l'immunogÃ©nicitÃ© et la sÃ©curitÃ© du vaccin Ã  ARNm COVID-19 BNT162b2 chez des participants adultes sans antÃ©cÃ©dents d'infection par le SARS CoV-2, administrÃ©s avec deux doses de vaccin (J1-J29) et chez des participants adultes ayant des antÃ©cÃ©dents documentÃ©s d'infection par le SRAS CoV-2 (de plus de 6 mois), administrÃ©s avec une seule dose de vaccin.",NA,False,False
ðŸŸ¥,,2019-002829-29,,"Combined Prevention of Sexually Transmitted Infections (STIs) in Men Who Have Sex with Men using oral TDF/FTC for HIV Pre-Exposure Prophylaxis (PrEP) 
 
 
 PrÃ©vention combinÃ©e des infections sexuellement transmissibles (IST) chez les hommes ayant des rapports sexuels avec des hommes utilisant le TDF/FTC par voie orale pour la prophylaxie prÃ©exposition au VIH (PrEP)",Doxyvac,False,False
